Hemispherx Biopharma, Inc. announced that on December 23, 2015, pursuant to a resolution of the Compensation Committee of the Board, the company notified Dr. William A. Carter, the chairman of the board, chief executive officer and chief scientific officer, that it was not renewing his Amended and Restated Engagement Agreement dated June 11, 2010. As a result, the agreement terminated on December 31, 2015 per its terms. The company has agreed to continue to pay Dr. Carter a base fee at the rate of $331,750 per year, payable monthly, for services that he renders to the company as a consultant.